COMPOSITIONS FOR USE IN IDENTIFICATION OF MIXED POPULATIONS OF BIOAGENTS

• US 20100204266A1
• Filed: 03/21/2008
• Published: 08/12/2010
• Est. Priority Date: 03/23/2007
• Status: Abandoned Application

• Current Assignee: Ibis Biosciences Incorporated (Abbott Laboratories)
• Original Assignee: Ibis Biosciences Incorporated (Abbott Laboratories)
• Inventors: Sampath, Rangarajan, Massire, Christian, Ecker, David J.
• Application Number:
  US12/532,803
• Publication Number:
  US 20100204266A1
• Time in Patent Office: Days
• US Class Current: 514/300
• CPC Class Codes: C12Q 1/689 for bacteria
• CPC Class Codes: C12Q 2531/113 PCR
• CPC Class Codes: C12Q 2565/627 being a mass spectrometer
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

The present invention provides oligonucleotide primers, compositions, and kits containing the same for rapid identification of bacterial bioagents and populations of bioagents which are members of the Staphylococcus bacterial genus by amplification of a segment of bioagent nucleic acid followed by molecular mass analysis.

Claims

1. A method for identifying a population genotype comprising the steps of:

(a) obtaining a sample suspected of comprising a population of bioagents;

(b) amplifying a nucleic acid from each of two or more bioagents from said population of bioagents in said sample using a primer pair that is configured to generate an amplicon from within a region defined by SEQ ID NO;

10, thereby generating amplicons from said nucleic acids;

(c) determining a molecular mass measurement for each of said amplicons using a mass spectrometer;

(d) calculating a base composition from each molecular mass measurement; and

(e) identifying a population genotype for said population of bioagents by comparing each of said base compositions calculated in step (d) to a database of base compositions indexed to the primer pair of step (b) and a known bioagent genotype.

2. The method of claim 1 wherein said primer pair further comprises a forward member that is 20 to 35 nucleobases in length and comprises at least 80% identity to a first portion of SEQ ID NO:

10 and a reverse member that is 20 to 35 nucleobases in length and comprises at least 80% reverse complementarity to a second portion of SEQ ID NO;

10.

3. The method of claim 2 wherein said forward member comprises at least 90% identity to said first portion of SEQ ID NO:

10.

4. The method of claim 2 wherein said forward member comprises at least 95% identity to said first portion of SEQ ID NO:

10.

5. The method of claim 2 wherein said forward member comprises at least 97% identity to said first portion of SEQ ID NO:

10.

6. The method of claim 2 wherein said forward primer pair member comprises SEQ ID NO:

2 with 0-8 nucleobase deletions, additions and/or substitutions.

7. The method of claim 2 wherein said forward primer pair member comprises SEQ ID NO:

3 with 0-8 nucleobase deletions, additions and/or substitutions.

8. The method of claim 2 wherein said forward primer pair member comprises SEQ ID NO:

4 with 0-8 nucleobase deletions, additions and/or substitutions.

9. The method of claim 2 wherein said reverse member comprises at least 90% reverse complementarity to said second portion of SEQ ID NO:

10.

10. The method of claim 2 wherein said reverse member comprises at least 95% reverse complementarity to said second portion of SEQ ID NO:

10.

11. The method of claim 2 wherein said reverse member comprises at least 97% reverse complementarity to said second portion of SEQ ID NO:

10.

12. The method of claim 2 wherein said reverse primer pair member comprises SEQ ID NO:

5 with 0-6 nucleobase deletions, additions and/or substitutions.

13. The method of claim 2 wherein said reverse primer pair member comprises SEQ ID NO:

6 with 0-8 nucleobase deletions, additions and/or substitutions.

14. The method of claim 2 wherein said reverse primer pair member comprises SEQ ID NO:

7 with 0-9 nucleobase deletions, additions and/or substitutions.

15. The method of claim 1 wherein either or both of said primer members comprises at least one modified nucleobase.

16. The method of claim 15 wherein said modified nucleobase is a mass modified nucleobase.

17. The method of claim 16 wherein said modified nucleobase is 5-Iodo-C.

18. The method of claim 15 wherein said modified nucleobase is a universal nucleobase.

19. The method of claim 18 wherein said modified nucleobase is inosine.

20. The method of claim 1 wherein either or both of said primer members comprise a non-templated 5′

T-residue.

21. The method of claim 1 wherein said population of bioagents comprises at least two bacteria belonging to the Staphylococcus genus.

22. The method of claim 21 wherein at least one of said bacteria is resistant to quinolone antimicrobial therapy.

23. The method of claim 21 wherein at least one of said bacteria is resistant to quinolone antimicrobial therapy and at least one of said bacteria is sensitive to quinolone antimicrobial therapy.

24. The method of claim 1 wherein said population of bioagents comprises at least two bacteria belonging to the Staphylococcus aureus species.

25. The method of claim 24 wherein at least one of said bacteria is resistant to quinolone antimicrobial therapy.

26. The method of claim 24 wherein at least one of said bacteria is resistant to quinolone antimicrobial therapy and at least one of said bacteria is sensitive to quinolone antimicrobial therapy.

27. The method of claim 1 wherein an antibiotic regimen tailored to treat the identified genotypes for the population of bioagents is delivered to the sample source.

28. The method of claim 1 wherein steps (a) to (e) are periodically repeated.

29. A method of reducing a population of bacteria in a person needing such a treatment comprising the steps of:

(a) obtaining from a person a sample suspected of comprising a population of bacterial bioagents;

(b) amplifying a nucleic acid from each of two or more bacterial bioagents in said sample using a primer pair that is configured to generate an amplicon from within a region of defined by SEQ ID NO;

10, thereby generating amplicons from said nucleic acids;

(c) determining a molecular mass measurement for each of said amplicons using a mass spectrometer;

(d) calculating a base composition from each molecular mass measurement;

(e) identifying a population genotype for said population of bioagents by comparing each of said base compositions calculated in step (d) to a database of base compositions indexed to the primer pair of step (b) and a known bioagent genotype; and

(f) administering to a person in need thereof an antibiotic regimen tailored to treat the identified genotypes for the population of bacterial bioagents.

30. The method of claim 29 wherein said primer pair further comprises a forward member that is 20 to 35 nucleobases in length and comprises at least 80% identity to a first portion of SEQ ID NO:

10 and a reverse member that is 20 to 35 nucleobases in length and comprises at least 80% reverse complementarity to a second portion of SEQ ID NO;

10.

31. The method of claim 30 wherein said forward member comprises at least 90% identity to said first portion of SEQ ID NO:

10.

32. The method of claim 30 wherein said forward member comprises at least 95% identity to said first portion of SEQ ID NO:

10.

33. The method of claim 30 wherein said forward member comprises at least 97% identity to said first portion of SEQ ID NO:

10.

34. The method of claim 30 wherein said forward primer pair member comprises SEQ ID NO:

2 with 0-8 nucleobase deletions, additions and/or substitutions.

35. The method of claim 30 wherein said forward primer pair member comprises SEQ ID NO:

3 with 0-8 nucleobase deletions, additions and/or substitutions.

36. The method of claim 30 wherein said forward primer pair member comprises SEQ ID NO:

4 with 0-8 nucleobase deletions, additions and/or substitutions.

37. The method of claim 30 wherein said reverse member comprises at least 90% reverse complementarity to said second portion of SEQ ID NO:

10.

38. The method of claim 30 wherein said reverse member comprises at least 95% reverse complementarity to said second portion of SEQ ID NO:

10.

39. The method of claim 30 wherein said reverse member comprises at least 97% reverse complementarity to said second portion of SEQ ID NO:

10.

40. The method of claim 30 wherein said reverse primer pair member comprises SEQ ID NO:

5 with 0-6 nucleobase deletions, additions and/or substitutions.

41. The method of claim 30 wherein said reverse primer pair member comprises SEQ ID NO:

6 with 0-8 nucleobase deletions, additions and/or substitutions.

42. The method of claim 30 wherein said reverse primer pair member comprises SEQ ID NO:

7 with 0-9 nucleobase deletions, additions and/or substitutions.

43. The method of claim 30 wherein either or both of said primer members comprises at least one modified nucleobase.

44. The method of claim 43 wherein said modified nucleobase is a mass modified nucleobase.

45. The method of claim 44 wherein said modified nucleobase is 5-Iodo-C.

46. The method of claim 43 wherein said modified nucleobase is a universal nucleobase.

47. The method of claim 46 wherein said modified nucleobase is inosine.

48. The method of claim 29 wherein either or both of said primer members comprise a non-templated 5′

T-residue.

49. The method of claim 29 wherein said population of bacterial bioagents comprises at least two bacteria belonging to the Staphylococcus genus.

50. The method of claim 49 wherein at least one of said bacteria is resistant to quinolone antimicrobial therapy.

51. The method of claim 49 wherein at least one of said bacteria is resistant to quinolone antimicrobial therapy and at least one of said bacteria is sensitive to quinolone antimicrobial therapy.

52. The method of claim 29 wherein said population of bacterial bioagents comprises at least two bacteria belonging to the Staphylococcus aureus species.

53. The method of claim 52 wherein at least one of said bacteria is resistant to quinolone antimicrobial therapy.

54. The method of claim 52 wherein at least one of said bacteria is resistant to quinolone antimicrobial therapy and at least one of said bacteria is sensitive to quinolone antimicrobial therapy.

55. The method of claim 29 wherein steps (a) to (e) are periodically repeated.

56. The method of claim 55 wherein an emerging genotype is identified in step (e) of one or more of said periodic repeats, further comprising modifying said antibiotic regimen to treat said emerging genotype.

57. The method of claim 29 wherein said antibiotic regimen comprises an antibiotic for treating quinolone resistant bacteria and an antibiotic for treating quinolone sensitive bacteria.

58. A composition of matter comprising a purified oligonucleotide primer pair wherein each primer member of said primer pair is 20 to 35 nucleobases in length and wherein the forward primer comprises at least 80% identity with a first portion of SEQ ID NO:

10 and the reverse primer comprises at least 80% reverse complementarity with a second portion of SEQ ID NO;

10.

59. The composition of claim 58 wherein the forward member comprises at least 90% identity to said first portion of SEQ ID NO:

10.

60. The composition of claim 58 wherein the forward member comprises at least 95% identity to said first portion of SEQ ID NO:

10.

61. The composition of claim 58 wherein the forward member comprises at least 97% identity to said first portion of SEQ ID NO:

10.

62. The composition of claim 58 wherein the forward primer pair member comprises SEQ ID NO:

2 with 0-8 nucleobase deletions, additions and/or substitutions.

63. The composition of claim 58 wherein the forward primer pair member comprises SEQ ID NO:

3 with 0-8 nucleobase deletions, additions and/or substitutions.

64. The composition of claim 58 wherein the forward primer pair member comprises SEQ ID NO:

4 with 0-8 nucleobase deletions, additions and/or substitutions.

65. The composition of claim 58 wherein the forward primer pair member comprises at least 80% identity with a portion of SEQ ID NO:

11.

66. The composition of claim 58 wherein the reverse member comprises at least 90% reverse complementarity to said second portion of SEQ ID NO:

10.

67. The composition of claim 58 wherein the reverse member comprises at least 95% reverse complementarity to said second portion of SEQ ID NO:

10.

68. The composition of claim 58 wherein the reverse member comprises at least 97% reverse complementarity to said second portion of SEQ ID NO:

10.

69. The composition of claim 58 wherein the reverse primer pair member comprises SEQ ID NO:

5 with 0-6 nucleobase deletions, additions and/or substitutions.

70. The composition of claim 58 wherein the reverse primer pair member comprises SEQ ID NO:

6 with 0-8 nucleobase deletions, additions and/or substitutions.

71. The composition of claim 58 wherein the reverse primer pair member comprises SEQ ID NO:

7 with 0-9 nucleobase deletions, additions and/or substitutions.

72. The composition of claim 58 wherein the reverse primer pair member comprises at least 80% reverse complementarity with a portion of SEQ ID NO:

12.

73. The composition of claim 58 wherein either or both of the primer members comprises at least one modified nucleobase.

74. The composition of claim 73 wherein the modified nucleobase is a mass modified nucleobase.

75. The composition of claim 74 wherein the modified nucleobase is 5-Iodo-C.

76. The composition of claim 73 wherein the modified nucleobase is a universal nucleobase.

77. The composition of claim 76 wherein the modified nucleobase is inosine.

78. The composition of claim 58 wherein either or both of the primer members comprise a non-templated 5′

T-residue.

79. The composition of claim 58 wherein said primer pair is configured to generate an amplicon of between about 45 and about 192 nucleobases in length comprising a region of SEQ ID NO:

10.